Comparative Pharmacology
Head-to-head clinical analysis: ENTACAPONE versus ONGENTYS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENTACAPONE versus ONGENTYS.
ENTACAPONE vs ONGENTYS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Entacapone is a selective and reversible inhibitor of catechol-O-methyltransferase (COMT), which inhibits the metabolism of levodopa to 3-O-methyldopa, thereby increasing the plasma half-life and bioavailability of levodopa in the brain.
Ongentys (opicapone) is a selective and reversible inhibitor of catechol-O-methyltransferase (COMT). By inhibiting COMT, it decreases the metabolism of levodopa to 3-O-methyldopa, thereby increasing plasma levodopa levels and enhancing its bioavailability in the brain, leading to improved dopaminergic effects.
200 mg orally administered concomitantly with each dose of carbidopa/levodopa, up to a maximum of 8 times daily (1600 mg/day).
50 mg orally once daily, taken at bedtime.
None Documented
None Documented
Clinical Note
moderateEntacapone + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Entacapone is combined with Fluticasone propionate."
Clinical Note
moderateEntacapone + Venlafaxine
"The risk or severity of adverse effects can be increased when Entacapone is combined with Venlafaxine."
Clinical Note
moderateEntacapone + Nefazodone
"The risk or severity of adverse effects can be increased when Entacapone is combined with Nefazodone."
Clinical Note
moderateTerminal elimination half-life is approximately 0.4–0.7 hours in the initial phase, with a terminal half-life of 2–2.5 hours, reflecting rapid elimination; clinically, entacapone is administered with each levodopa/carbidopa dose to inhibit COMT.
The terminal elimination half-life of opicapone is approximately 1 to 2 hours at low doses, but at therapeutic doses (50 mg) it exhibits nonlinear pharmacokinetics with an effective half-life of about 12 to 16 hours due to tight binding to COMT enzyme, allowing once-daily dosing.
Primarily hepatic metabolism with biliary excretion: about 90% of dose excreted in feces, 10% in urine (as metabolites).
Following oral administration, approximately 30% of the dose is excreted in urine as unchanged opicapone, with an additional 10% as glucuronide conjugates. The remainder is eliminated via biliary/fecal routes, accounting for about 60% of the dose.
Category A/B
Category C
COMT Inhibitor
COMT Inhibitor
Entacapone + Stiripentol
"The risk or severity of adverse effects can be increased when Entacapone is combined with Stiripentol."